Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus.
RNA viruses replicate near the error threshold for maintenance of genetic information, and an increase in mutation frequency during replication may drive RNA viruses to extinction in a process termed lethal mutagenesis. This report addresses the efficiency of extinction (versus escape from extinction) of foot-and-mouth disease virus (FMDV) by combinations of the mutagenic base analog 5-fluorouracil (FU) and the antiviral inhibitors guanidine hydrochloride (G) and heparin (H). Selection of G- or H-resistant, extinction-escape mutants occurred with low-fitness virus only in the absence of FU and with high-fitness virus with some mutagen-inhibitor combinations tested. The combination of FU, G, and H prevented selection of extinction-escape mutants in all cases examined, and extinction of high-fitness FMDV could not be achieved by equivalent inhibitory activity exerted by the nonmutagenic agents. The G-resistant phenotype was mapped in nonstructural protein 2C by introducing the relevant mutations in infectious cDNA clones. Decreases in FMDV infectivity were accompanied by modest decreases in the intracellular and extracellular levels of FMDV RNA, maximal intracellular concentrations of FU triphosphate, and a decrease in the intracellular concentrations of UTP. In addition to indicating a key participation of mutagenesis in virus extinction, the results suggest that picornaviruses provide versatile experimental systems to approach the problem of extinction failure associated with inhibitor-escape mutants during treatments based on enhanced mutagenesis.
Pariente
Nonia
N
Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain.
Airaksinen
Antero
A
Domingo
Esteban
E
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D006224:Cricetinae; D004338:Drug Combinations; D005472:Fluorouracil / Q000494:pharmacology*; D029544:Foot-and-Mouth Disease Virus / Q000187:drug effects / Q000235:genetics / Q000254:growth & development* / Q000472:pathogenicity; D019791:Guanidine / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D009153:Mutagens / Q000494:pharmacology*; D009154:Mutation
D000998:Antiviral Agents; D004338:Drug Combinations; D009153:Mutagens; D006493:Heparin; D019791:Guanidine; D005472:Fluorouracil